Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken
Authors:
Open Access
- 18 December 2023
- journal article
- research article
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 79 (1) , 26-33
Abstract
Despite the low prevalence of each rare disease, the total burden is high. Patients with rare diseases encounter numerous barriers, including delayed diagnosis and limited access to high-quality treatments. In order to tackle these challenges, the European Commission launched the European Reference Networks (ERNs), cross-border networks of healthcare providers and patients representatives. In parallel, the aims and structure of these ERNs were translated at the federal and regional levels, resulting in the creation of the Flemish Network of Rare Diseases. In line with the mission of the ERNs and to ensure equal access to care, we describe as first patient pathways for systemic sclerosis (SSc), as a pilot model for other rare connective and musculoskeletal diseases. Consensus was reached on following key messages: 1. Patients with SSc should have multidisciplinary clinical and investigational evaluations in a tertiary reference expert centre at baseline, and subsequently every three to 5 years. Intermediately, a yearly clinical evaluation should be provided in the reference centre, whilst SSc technical evaluations are permissionably executed in a centre that follows SSc-specific clinical practice guidelines. In between, monitoring can take place in secondary care units, under the condition that qualitative examinations and care including interactive multidisciplinary consultations can be provided. 2. Patients with early diffuse cutaneous SSc, (progressive) interstitial lung disease and/or pulmonary arterial hypertension should undergo regular evaluations in specialised tertiary care reference institutions. 3. Monitoring of patients with progressive interstitial lung disease and/or pulmonary (arterial) hypertension will be done in agreement with experts of ERN LUNG.Keywords
Funding Information
- educational grant of Janssen-Cilag (EV00351581)
This publication has 25 references indexed in Scilit:
- Mapping and predicting mortality from systemic sclerosisAnnals of the Rheumatic Diseases, 2017
- Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)Annals of the Rheumatic Diseases, 2017
- Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseenOrphanet Journal of Rare Diseases, 2017
- Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug actOrphanet Journal of Rare Diseases, 2016
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2013
- Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial HypertensionArthritis & Rheumatism, 2013
- The Belgian Systemic Sclerosis Cohort: Correlations Between Disease Severity Scores, Cutaneous Subsets, and Autoantibody ProfileThe Journal of Rheumatology, 2012
- Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long‐term survivalArthritis & Rheumatism, 2011
- Rare Diseases Epidemiology Research2010
- Over-representation of construction-related occupations in male patients with systemic sclerosisAnnals of the Rheumatic Diseases, 2008